ETON Historical PE Ratio Notes

— Eton Pharmaceuticals (ETON) is a specialty pharmaceutical company focused on developing, acquiring, and commercializing innovative treatments for rare diseases and niche markets within the U.S. healthcare system. ETON often targets products with relatively small patient populations but significant unmet medical needs, including orphan drugs and ready-to-use injectable formulations. Understanding its business model is crucial when examining ETON’s historical price-to-earnings (PE) ratio. Given the company’s focus on development and early commercialization phases, earnings have historically been volatile or negative due to significant research & development, regulatory, and launch expenses, frequently resulting in either very high PE ratios or, in loss-making years, undefined or negative PE values. As a result, charts and tables showing historical PE ratios for ETON may reflect substantial swings or even gaps, which underscore the importance of considering not just reported earnings, but the anticipated future profitability based on product launches & approvals. Investors should keep in mind that for companies like ETON, valuation multiples can diverge sharply from more established pharmaceutical companies, especially during periods of intensive pipeline investment or just ahead of first commercial revenues.

On this page we presented the Eton Pharmaceuticals Historical PE Ratio information for Eton Pharmaceuticals' stock. The average ETON historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 48.9. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average ETON historical PE based on this TTM earnings result method is 86.5. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this ETON historical PE result, against the recent PE: when this page was posted on 5/15/2026, the most recent closing price for ETON had been 30.26, and the most recent quarterly earnings result, annualized, was 0.56. Meanwhile, the most recent TTM earnings summed to 0.27. From these numbers, we calculate the recent ETON PE on 5/15/2026 based on annualized quarterly EPS was 54.0. Based on ETON's history, that recent PE is elevated relative to the historical average, with the recent PE 10.4% higher than the historical average PE across our data set for Eton Pharmaceuticals. Looking at the recent ETON PE on 5/15/2026 based on TTM EPS, we calculate the ratio at 112.1. Based on ETON's history, that recent PE is elevated relative to the historical average, with the recent PE 29.6% higher than the historical average PE across our Eton Pharmaceuticals data set with TTM EPS used in the calculation at each period.

Another interesting ETON historical PE Ratio calculation we look at is to take the median earnings per share of the last four quarters for ETON, and then annualize the resulting value... with that annualized number then being used in the PE calculation. To walk through this math for ETON, we start with the past four EPS numbers and we first sort them from lowest to highest: -0.10, 0.04, 0.14, and 0.19. We then toss out the highest and lowest result, and then take the average of those two middle numbers — 0.04 and 0.14 — which gives us the median of 0.09. Basically the way to think about this 0.09 number is this: for the trailing four earnings reports, 0.09 marks the "middle ground" number where ETON has reported a value higher than 0.09 half the time, and has reported a value lower than 0.09 half the time. Annualizing that median value then gets us to 0.36/share, which we use as the denominator in our next PE calculation. With 30.26 as the numerator (as of 5/15/2026), the calculation is then 30.26 / 0.36 = 84.1 as the ETON PE ratio as of 5/15/2026, based on that annualized median value we calculated.

For self directed investors doing their due diligence on ETON or any other given stock, valuation analysis for ETON can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Eton Pharmaceuticals PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for ETON. Thanks for visiting, and the next time you need to research ETON Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.